Navigation Links
UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers
Date:4/24/2008

f neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with Cimzia(R); the causal relationship to Cimzia(R) remains unclear. Exercise caution in considering the use of Cimzia(R) in patients with these disorders.

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with Cimzia(R). The causal relationship of these events to Cimzia(R) remains unclear. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on Cimzia(R). Consider discontinuation of Cimzia(R) therapy in patients with confirmed significant hematologic abnormalities.

Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of Cimzia(R) and anakinra is not recommended.

Interference with certain coagulation assays has been detected in patients treated with Cimzia(R). There is no evidence that Cimzia(R) therapy has an effect on in vivo coagulation.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Cimzia(R) has not been formally studied in patients with CHF. Exercise caution when using Cimzia(R) in patients who have heart failure and monitor them carefully.

Treatment with Cimzia(R) may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

Do not administer live vaccines or attenuated vaccines concurrently with Cimzia(R).

In controlled Crohn's clinical trials, the most common adverse events that occurred
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ... the occasion; they are specially designed for those who want ...
(Date:12/26/2014)... 26, 2014 The Biofeedback Federation of ... 24-28, 2015 in Rome, Italy and is hosted by ... workshops on a wide variety of topics such ... peak performance training in athletes. The scientific program will ... , Biofeedback monitoring allows clients to see what is ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... The click strand woven ... and durability. Today, the business announces a click ... until Jan. 30, 2015. , Click strand woven ... BambooFlooringChina.com is a well-known brand in the bamboo ... find a reliable bamboo flooring supplier. , “We ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... come up in Ludhiana and a huge clientele of females ... ,Neelam Handa, who started a boutique as ... any celebrated fashion designer. ,Neelams is an exclusive ... saris and lehengas. ,Her commitment to quality ...
... ringing as cases of tobacco-related cancer increase in Mizoram, which ... ,According to authorities, Mizoram has the highest incidence of lung ... being used in various forms including cigarettes and "zou zeal", ... nual", traditional forms of tobacco are also popular, both among ...
... rely on a new, non-surgical procedure called Radio-frequency ablation (RFA), ... , Louis Bershad, after he was diagnosed with a malignant ... seemed to go black, then I could only envision a ... intensive chemotherapy, both of which can have complications and result ...
... Britain have claimed that the popularity of cashmere, which is ... more people are experiencing trouble with moths . ... the number of calls received to deal with moths has risen ... currently receiving a high number of calls about moths. There is ...
... that a class of commonly prescribed antidepressants may be ... older men and women . ,The antidepressant ... depression by inhibiting the protein that transports serotonin, a ... information in the articles, and which has recently been ...
... School of Medicine has discovered the first gene linked to ... children . ,The finding, published in the American ... scoliosis have remained a mystery for centuries. ,It ... CHD7 gene, which is thought to play a critical role ...
Cached Medicine News:Health News:Boutiques Flourish in Ludhiana 2Health News:Concern in Mizoram Over Growing Tobacco-related Diseases 2Health News:Radio-frequency Ablation Offers Hope for People With Inoperable Kidney Tumours 2Health News:Brits Experiencing Moth Trouble With Their Cashmeres 2Health News:Common Antidepressants Linked to Increased Bone Loss in Older Adults 2Health News:Common Antidepressants Linked to Increased Bone Loss in Older Adults 3Health News:First Gene Linked to Scoliosis Identified 2
(Date:12/24/2014)... -- Actavis plc (NYSE: ACT ) today ... response letter from the U.S. Food and Drug ... for the fixed-dose combination (FDC) of nebivolol and ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... a complete response letter, Actavis remains committed to ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... HIGHLIGHTS :2012 Results (all percentages are to comparable periods ... 5% to $665 million, a new quarterly high. Q1 sales grew ... growth of 4% and 1%, respectively.  Acquisitions contributed 4% to sales ... sales by 2%. , Q1 2012 reported diluted ...
... LAKE SUCCESS, N.Y., April 24, 2012  Polar ( www.polarusa.com ... training technology, today announced the appointment of Herb Baer ... role, Baer will be responsible for the overall direction ... of the business including consumer fitness, running, cycling, physical ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13Herb Baer Appointed President of Polar USA 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: